Abstract
The second hereditary breast cancer gene, BRCA2, was recently isolated1. Germline mutations of this gene predispose carriers to breast cancer, and, to a lesser extent, ovarian cancer. Loss of heterozygosity (LOH) at the BRCA2 locus has been observed in 30–40% of sporadic breast and ovarian tumours, implying thatBRCA2 may act as a tumour suppressor gene in a proportion of sporadic cases 2–5. To define the role of BRCA2 in sporadic breast and ovarian cancer, we screened the entire gene for mutations using a combination of techniques in 70 primary breast carcinomas and in 55 primary epithelial ovarian carcinomas. Our analysis revealed alterations in 2/70 breast tumours and none of the ovarian carcinomas. One alteration found in the breast cancers was a 2-basepair (bp) deletion (4710delAG) which was subsequently shown to be a germline mutation, the other was a somatic missense mutation (Asp3095Glu) of unknown significance. Our results suggest that BRCA2 is a very infrequent target for somatic inactivation in breast and ovarian carcinomas, similar to the results obtained torBRCAL
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).
Lundberg, C. et al. Loss of heterozygosity in human ductal breast tumours indicates a recessive mutation on chromosome 13. Proc. Natl. Acad. Sci. USA 84, 2372–2376 (1987).
Kim, T.M. et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian eptithelial tumors and is associated with normal retinoblastoma expression. Cancer Res. 54, 605–609 (1994).
Collins, N. et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene chromosome 13q12–13. Oncogene 10, 1673–1675 (1995).
Cleton-Jansen, A.M. et al.Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12–13. Br.J.Cancer 72, 1241–1244 (1995).
Phelan, C.M. et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet. 13, 120–122 (1996).
Futreal, P.A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120–122 (1994).
Merajver, S.A. et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 9, 439–443 (1995).
Hosking, L. et al. A somatic BRCA1 mutation in an ovarian tumour. Nature Genet. 9, 343–344 (1995).
Takahashi, H. et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 55, 2998–3002 (1995).
Kerangueven, F. et al. Patterns of loss of heterzygosity at loci from chromosome arm 13q suggest a possible involvement of BRCA2 in sporadic breast tumors. Genes Chrom. Cancer 13, 291–294 (1995).
Chen, Y et al.Aberrant subcellular localization of BRCA1 in breast cancer. Science 270, 789–791 (1995).
Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L. & Holt, J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9, 444–450 (1995).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lancaster, J., Wooster, R., Mangion, J. et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13, 238–240 (1996). https://doi.org/10.1038/ng0696-238
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0696-238
This article is cited by
-
In-Silico Analyses of Nonsynonymous Variants in the BRCA1 Gene
Biochemical Genetics (2021)
-
Comprehensive study for BRCA1 and BRCA2 entire coding regions in breast cancer
Clinical and Translational Oncology (2021)
-
Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays
Biological Procedures Online (2020)
-
A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors
Medical Oncology (2018)
-
DNA Mutations May Not Be the Cause of Cancer
Oncology and Therapy (2017)
